ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain

Trial ID or NCT#

NCT00981578

Status

not recruiting iconNOT RECRUITING

Purpose

A study to evaluate the safety and initial effectiveness of the ExAblate 2100 Conformal Bone System in the treatment of pain resulting from metastatic bone tumors.

Official Title

A Feasibility Study to Evaluate the Safety and Initial Effectiveness of ExAblate MR Guided Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. 1. Men and women age 18 and older 2. Patients who are able and willing to give consent and able to attend all study visits 3. Patients who are suffering from symptoms of bone metastases 4. One to 3 painful lesions. 5. Targeted tumor(s) are ExAblate device accessible and are located in ribs, extremities (excluding joints), pelvis, shoulders and in the posterior aspects of the following spinal vertebra: Lumbar vertebra (L3 - L5), Sacral vertebra (S1 - S5) 6. Patients with persistent distinguishable pain associated with up to 3 tumors of which a maximum of 2 tumors will be treated: o If patient has pain from additional sites that are not planned for treatment, the pain from the additional sites must be evaluated as being less intense by at least 2 points on the NRS compared to the site(s) to be treated. 7. Patient with NRS (0-10 scale) pain score ≥ 4 at the targeted tumors (i.e: both tumors targeted for treatment must have NRS ≥ 4) irrespective of medication 8. Targeted tumors (most painful) size up to 8 cm in diameter 9. Patient whose targeted (most painful) tumors are on bone and bone-lesion interface is deeper than 1cm from the skin. 10. Targeted (most painful) tumors clearly visible by non-contrast MRI, and ExAblate MRgFUS device accessible 11. Able to communicate sensations during the ExAblate MRgFUS treatment 12. At least 2 weeks since chemotherapy 13. No radiation therapy to targeted (most painful) tumors in the past two weeks
Exclusion Criteria:
  1. 1. Patients who either - Need surgical stabilization of the affected weight bearing bony structure (>7 fracture risk score, see Section 6.9) OR - Targeted tumor is at an impending fracture site of the weigh bearing bone (>7 on fracture risk score, see Section 6.9). OR o Patients with surgical stabilization of tumor site with metallic hardware 2. More than 3 painful lesions or more than 2 requiring immediate localized treatment 3. The targeted tumor(s) is (are) less than 2 points more painful compared to other non-targeted painful lesions on the site specific NRS. 4. Targeted tumor is in the skull 5. Patients on dialysis 6. Patients with life expectancy < 6-Months 7. Patients with an acute medical condition (e.g., pneumonia, sepsis) that is expected to hinder them from completing this study. 8. Patients with unstable cardiac status including: - Unstable angina pectoris on medication - Patients with documented myocardial infarction within six months of protocol entry - Congestive heart failure requiring medication (other than diuretic) - Patients on anti-arrhythmic drugs 9. Severe hypertension (diastolic BP > 100 on medication) 10. Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc. 11. Patients with an active infection or severe hematological, neurological, or other uncontrolled disease. 12. Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or Magnevist) including advanced kidney disease 13. KPS Score < 60 (See "Definitions" below) 14. Severe cerebrovascular disease (multiple CVA or CVA within 6 months) 15. Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (can be up to 4 hrs of total table time.) 16. Target (most painful) tumor-bone interface is less then 1cm from nerve bundles, bowels or bladder. 17. Are participating or have participated in another clinical trial for the palliation of their targeted bone metastasis tumors in the last 30 days 18. Patients receiving chemotherapy or radiation (i.e., to the targeted lesion (s)) within the last two weeks 19. Patients unable to communicate with the investigator and staff. 20. Patients with persistent undistinguishable pain (pain source unidentifiable) 21. Targeted (most painful) tumors size > 8 cm in diameter 22. Targeted (most painful) tumors: - NOT visible by non-contrast MRI, OR - NOT accessible to ExAblate device

Investigator(s)

David Hovsepian, MD
David Hovsepian, MD
Interventional radiologist, Radiologist
Clinical Professor, Radiology Clinical Professor, Radiology - Pediatric Radiology
Heather Wakelee
Heather Wakelee
Medical oncologist, Thoracic specialist
Winston Chen and Phyllis Huang Professor
Pejman Ghanouni, MD, PhD
Pejman Ghanouni, MD, PhD
Radiologist
Associate Professor of Radiology (General Radiology) and, by courtesy, of Neurosurgery, of Obstetrics and Gynecology and of Urology
Nishita Kothary, MD
Nishita Kothary, MD
Interventional radiologist
Professor of Radiology (Interventional Radiology)

Contact us to find out if this trial is right for you.

Contact

CCTO
650-498-7061